On July 1, Ralph Schlosstein, Evercore’s chairman emeritus and BlackRock’s co-founder, joined ‘Closing Bell Overtime’ on CNBC to talk about his outlook for markets heading into the second half of the year. Schlosstein explained that it’s impossible to say that tariffs are entirely behind us, as the path of the president’s tariff discussions and the reactions of trading partners remain uncertain. However, he expressed cautious optimism and noted a strong desire from both the US government and its negotiating counterparts to reach the least disruptive settlement possible. While he acknowledged that there might be some mini tantrums, he overall expects no major disruptions from tariffs in H2.
Schlosstein also stated that while predicting future economic statistics with certainty is impossible, the trend for inflation appears positive and lays a strong foundation for a September rate cut. He also observed a slight loosening in the labor markets, which would support a downward move in interest rates. He concluded that the next directional change in Fed interest rates would be downward. The only remaining question was the number of cuts this year. Schlosstein expected two, and if not two, then three rather than just one. This is because he believes that there was sufficient room in both inflation and employment statistics to gradually move the Fed funds rate back towards a neutral level.
That being said, 11 best hot stocks to buy according to Wall Street analysts.
A financial analyst on a business call, studying a portfolio of stocks.
Methodology
We sifted through different stock screeners to compile a list of the hot stocks with the highest gains over the past 1 month (over 15%). We then selected the top 11 stocks with an upside potential of over 25% as of July 3. The stocks are ranked in ascending order of their upside potential. We have also added the hedge fund sentiment for each stock, as of Q1 2025, which was sourced from Insider Monkey’s database.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (see more details here).
11 Best Hot Stocks to Buy According to Wall Street Analysts
11. POSCO Holdings Inc. (NYSE:PKX)
Gain Over the Past 1 Month: 25.58%
Number of Hedge Fund Holders: 12
Average Upside Potential as of July 3: 20.24%
POSCO Holdings Inc. (NYSE:PKX) is one of the best hot stocks to buy according to Wall Street analysts. On July 1, POSCO Holdings announced its agreement to construct a pilot lithium processing plant in the US. This is a collaboration with Australia’s Anson Resources and aims to support POSCO’s EV battery raw materials supply chain while reducing its reliance on Chinese suppliers.
This is in response to new import restrictions imposed by the Trump administration in the US. The two companies have formalized their partnership through an MoU. The new pilot plant is slated for construction next year in Green River City, Utah. Its primary purpose will be to evaluate the commercial viability of POSCO’s proprietary Direct Lithium Extraction/DLE technology for large-scale production.
POSCO has been developing this innovative technology since 2016, and it extracts lithium from large and low-concentration brine lakes without solely relying on natural evaporation. Anson Resources possesses the mining rights for the lithium brine site in Utah, where the plant will be located. This venture will be the first time a South Korean company directly produces lithium in North America. Unlike some domestic competitors, POSCO is engaging in direct production.
POSCO Holdings Inc. (NYSE:PKX) is an integrated steel producer in Korea and internationally.
10. Summit Therapeutics Inc. (NASDAQ:SMMT)
Gain Over the Past 1 Month: 25.51%
Number of Hedge Fund Holders: 20
Average Upside Potential as of July 3: 42.57%
Summit Therapeutics Inc. (NASDAQ:SMMT) is one of the best hot stocks to buy according to Wall Street analysts. On July 3, Bloomberg News reported that AstraZeneca (NASDAQ:AZN) is in discussions with Summit Therapeutics for a licensing agreement concerning an experimental lung cancer drug, with a potential value of up to $15 billion.
The proposed deal for the drug, which is known as ivonescimab, could involve an upfront payment of several billion dollars to Summit, in addition to future milestone payments. However, the talks are ongoing and could still fall apart. Summit might even choose to partner with a different company. Neither Summit nor AstraZeneca has officially commented on the report.
Summit Therapeutics secured the rights to ivonescimab through a separate deal worth up to $5 billion with China-based Akeso in December 2022. Under that agreement, Summit gained exclusive rights to develop and commercialize ivonescimab in the US, Canada, Europe, and Japan, while Akeso (OTC:AKESF) retained rights for other regions, including China. The deal included an upfront payment of $500 million to Akeso and potential regulatory and commercial milestones of up to $4.5 billion.
Summit Therapeutics Inc. (NASDAQ:SMMT) is a biopharmaceutical company that discovers, develops, and commercializes patient, physician, caregiver, and societal-friendly medicinal therapies. AstraZeneca (NASDAQ:AZN) is a biopharmaceutical company that discovers, develops, manufactures, and commercializes prescription medicines.
9. Apogee Therapeutics Inc. (NASDAQ:APGE)
Gain Over the Past 1 Month: 30.03%
Number of Hedge Fund Holders: 36
Average Upside Potential as of July 3: 94.90%
Apogee Therapeutics Inc. (NASDAQ:APGE) is one of the best hot stocks to buy according to Wall Street analysts. Earlier in May, Apogee Therapeutics announced positive interim results from its Phase 1b trial of APG808. APG808 is a novel and half-life extended IL-4Rα antibody being developed for the treatment of various inflammatory and immunology (I&I) conditions, such as atopic dermatitis/AD, asthma, eosinophilic esophagitis/EoE, and chronic obstructive pulmonary disease/COPD.
The Phase 1b trial was a double-blind, placebo-controlled, and multiple-dose study that evaluated the safety, tolerability, and initial efficacy of APG808 in 22 adult patients with mild-to-moderate asthma. Results from the trial showed that APG808 was well tolerated through 12 weeks of follow-up, with a safety profile consistent with other anti-IL-4Rα class drugs. No severe adverse events were reported, and no adverse events led to study discontinuation.
APG808 is a novel subcutaneous monoclonal antibody targeting IL-4Rα, which is a clinically validated target across eight Type 2 allergic diseases. Preclinical studies indicated that APG808 has similar binding properties and femtomolar affinity for IL-4Rα as Dupixent and showed similar inhibition. Asthma, which is a common non-communicable disease, is estimated to affect 40 million adults and 12 million children across the US, France, Germany, Italy, Japan, Spain, and the UK.
Apogee Therapeutics Inc. (NASDAQ:APGE) is a clinical-stage biotechnology company that develops novel biologics for the treatment of various inflammatory and immunological indications.
8. Globalstar Inc. (NASDAQ:GSAT)
Gain Over the Past 1 Month: 27.01%
Number of Hedge Fund Holders: 18
Average Upside Potential as of July 3: 110.67%
Globalstar Inc. (NASDAQ:GSAT) is one of the best hot stocks to buy according to Wall Street analysts. On June 30, Globalstar announced the successful installation of Clifton-8. This 6-meter tracking antenna is the first dedicated to Globalstar’s upcoming C-3 mobile satellite system. It marked the official commencement of a significant global expansion of the company’s ground infrastructure for its new Extended Mobile Satellite Services/MSS Network.
The initial installation took place at Globalstar’s largest and longest-operating ground station in Clifton, Texas. The site has been providing continuous service for over 2 decades and plays a crucial role in supporting satellite coverage across the continental US, Mexico, and Canada. Clifton-8 is the eighth tracking antenna installed at this particular station and is the first of 5 new antennas planned for the Clifton facility to specifically support the C-3 system.
The installation of Clifton-8 is the initial step in a broader and months-long process. Globalstar plans to deploy 90+ new antennas across ~35 ground stations located in 25 countries and territories worldwide. This initiative involves both upgrades to existing ground stations and the construction of new facilities.
Globalstar Inc. (NASDAQ:GSAT) provides mobile satellite services in the US, Canada, Europe, Central and South America, and internationally.
7. Citius Pharmaceuticals Inc. (NASDAQ:CTXR)
Gain Over the Past 1 Month: 154.02%
Number of Hedge Fund Holders: 1
Average Upside Potential as of July 3: 127.27%
Citius Pharmaceuticals Inc. (NASDAQ:CTXR) is one of the best hot stocks to buy according to Wall Street analysts. In the middle of June, Citius Oncology, which is an oncology-focused subsidiary of Citius Pharmaceuticals, announced that it is nearing completion of preparations for the commercial launch of LYMPHIR. LYMPHIR is an FDA-approved immunotherapy for the treatment of adults with relapsed or refractory cutaneous T-cell lymphoma/CTCL, indicated for Stage I-III disease after at least one prior systemic therapy.
The company anticipates a US launch of LYMPHIR in H2 2025. Citius Oncology has completed commercial-scale manufacturing of LYMPHIR, with sufficient packaged and labeled inventory to meet projected demand for 12 to 18 months post-launch. The product supports a shelf life of 60 months. To facilitate broad access and timely delivery across the US, Citius Oncology has executed one and is finalizing other distribution services agreements with multiple top-tier global pharmaceutical logistics partners.
The commercial team has developed a targeted launch strategy using a proprietary GenAI model to identify and engage key accounts. A suite of marketing and educational materials, such as clinical guides, dosing protocols, and disease awareness content, has been developed for providers, patients, and caregivers. LYMPHIR’s inclusion in the National Comprehensive Cancer Network/NCCN Clinical Practice Guidelines, along with the assignment of a permanent J-code under HCPCS and ongoing engagement with payors, positions the product for efficient reimbursement and coverage upon launch.
Citius Pharmaceuticals Inc. (NASDAQ:CTXR) is a biopharmaceutical company that develops and commercializes critical care products.
6. UroGen Pharma Ltd. (NASDAQ:URGN)
Gain Over the Past 1 Month: 176.02%
Number of Hedge Fund Holders: 31
Average Upside Potential as of July 3: 143.00%
UroGen Pharma Ltd. (NASDAQ:URGN) is one of the best hot stocks to buy according to Wall Street analysts. In mid-June, UroGen Pharma announced that the US FDA had approved ZUSDURI (mitomycin) for intravesical solution. This marked ZUSDURI as the first and only FDA-approved medication for adults with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC).
ZUSDURI was formerly known as UGN-102 and is an innovative drug formulation of mitomycin combined with a sterile hydrogel, using UroGen’s proprietary sustained-release RTGel technology. This design allows for potent tumor ablation through non-surgical means, delivered directly into the bladder via a urinary catheter in an outpatient procedure by a trained healthcare professional.
The approval is supported by positive results from the pivotal Phase 3 ENVISION trial. The trial demonstrated that 78% of patients achieved a complete response at 3 months. Furthermore, 79% of those responders maintained their complete response at 12 months after the 3-month visit. The medication exhibited a manageable safety profile as well.
UroGen Pharma Ltd. (NASDAQ:URGN) develops and commercializes solutions for urothelial and specialty cancers.
5. Prime Medicine Inc. (NASDAQ:PRME)
Gain Over the Past 1 Month: 135.61%
Number of Hedge Fund Holders: 15
Average Upside Potential as of July 3: 173.31%
Prime Medicine Inc. (NASDAQ:PRME) is one of the best hot stocks to buy according to Wall Street analysts. In May, Prime Medicine announced a strategic restructuring, which included a reprioritization of its pipeline, cost-cutting measures, and a leadership transition. The company will now focus its internal efforts on in vivo programs for large genetic liver diseases, specifically Wilson’s Disease and Alpha-1 Antitrypsin Deficiency/AATD, and continue its in vivo Cystic Fibrosis program with external support, as well as partnered programs for Prime Edited CAR-T products.
This shift follows the announcement of initial positive data from the Phase 1/2 clinical trial of PM359 in Chronic Granulomatous Disease/CGD, which provided clinical proof-of-concept for Prime Editing as a transformative gene editing technology.
However, Prime Medicine is now exploring options for the continued clinical development of PM359 external to the company and ceasing further internal efforts in X-linked CGD. For its internal programs, Prime Medicine expects to file an Investigational New Drug/IND application and/or Clinical Trial Application/CTA for its Wilson’s Disease program in H1 2026, and for its AATD program in mid-2026. Initial clinical data from both programs are anticipated in 2027.
Prime Medicine Inc. (NASDAQ:PRME) is a biotechnology company that delivers genetic therapies to address the spectrum of diseases by deploying gene editing technology in the US.
4. Nektar Therapeutics (NASDAQ:NKTR)
Gain Over the Past 1 Month: 121.27%
Number of Hedge Fund Holders: 20
Average Upside Potential as of July 3: 202.91%
Nektar Therapeutics (NASDAQ:NKTR) is one of the best hot stocks to buy according to Wall Street analysts. On June 24, Nektar Therapeutics announced positive results from its mid-stage REZOLVE-AD study for rezpegaldesleukin, which is an eczema treatment.
The Phase 2b REZOLVE-AD study evaluated rezpegaldesleukin in 393 patients with moderate-to-severe atopic dermatitis (eczema), who had not previously received biologic or JAK inhibitor therapies. Patients received 3 under-the-skin injections of the drug. After 16 weeks, patients showed improvements in symptoms as measured by the Eczema Area and Severity Index/EASI.
Unlike many existing biologic treatments that block inflammatory cytokines, rezpegaldesleukin works by boosting the body’s natural anti-inflammatory mechanisms. The safety profile of rezpegaldesleukin was generally favorable, with mild to moderate injection site reactions being the most common adverse event, occurring in 69.7% of treated patients. These reactions were mostly mild to moderate, self-resolved, and did not lead to discontinuation. Nektar Therapeutics plans to present these 16-week induction data at a scientific meeting later in 2025.
Nektar Therapeutics (NASDAQ:NKTR) is a biopharmaceutical company that discovers and develops therapies that selectively modulate the immune system to treat autoimmune disorders internationally.
3. ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA)
Gain Over the Past 1 Month: 129.82%
Number of Hedge Fund Holders: 1
Average Upside Potential as of July 3: 211.91%
ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA) is one of the best hot stocks to buy according to Wall Street analysts. On July 3, ImmunoPrecise Antibodies announced significant validation for its proprietary epitope mapping platform, called LENSai. This platform is powered by IPA’s patented HYFT technology and has shown its ability to accurately predict antibody binding sites even on therapeutic targets it has never encountered before in its training data.
A new benchmark study tested LENSai on 30 antibody-protein pairs, 17 of which were entirely new to the platform, so LENSai had no prior exposure to these specific antibodies, targets, or complexes. Despite this, LENSai achieved prediction scores, measured by AUC (Area Under the Curve), that were nearly identical to those obtained from its original training data.
The consistent high performance on unseen complexes confirms LENSai’s generalizability and its ability to reliably analyze and predict antibody binding for diverse biological structures, achieving near-crystallography precision. Traditional epitope mapping methods can take months and require extensive wet-lab work and expensive materials. In contrast, LENSai delivers results in hours using only digital sequences. ImmunoPrecise is already integrating LENSai into collaborations with major pharmaceutical and biotech companies, as well as scaling access through secure APIs and custom partnerships.
ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA) is a techbio company that uses multi-omics modeling and complex AI through a series of proprietary and patented technologies, and supports the discovery and development of therapeutic antibodies.
2. Skye Bioscience Inc. (NASDAQ:SKYE)
Gain Over the Past 1 Month: 105.80%
Number of Hedge Fund Holders: 11
Average Upside Potential as of July 3: 247.07%
Skye Bioscience Inc. (NASDAQ:SKYE) is one of the best hot stocks to buy according to Wall Street analysts. On June 23, Skye Bioscience unveiled its “Anatomy of Progress” nimacimab development update video series. This coincided with the presentation of data related to nimacimab at the American Diabetes Association’s/ADA 85th Scientific Sessions, which was held from June 20 to 23 this year in Chicago, Illinois.
The four-part “Anatomy of Progress” video series highlights unmet needs in obesity treatment, the benefits of nimacimab as a peripheral CB1-receptor-targeting antibody for healthy weight loss, and its development progress. Nimacimab’s unique mechanism targets receptors in the periphery while being greater than 99% excluded from the brain. This peripheral restriction aims to deliver weight loss and metabolic benefits similar to first-gen CB1 inhibitors, but without the neuropsychiatric side effects that plagued earlier small-molecule counterparts.
Skye Bioscience is currently conducting a Phase 2a clinical trial in obesity for nimacimab, which is a negative allosteric modulating antibody that peripherally inhibits CB1. This study is also assessing nimacimab in combination with a GLP-1R agonist (Wegovy). Interim data from the Phase 2a clinical trial are expected in late Q3 or early Q4 2025, after the initial patient cohort completes a 26-week treatment period.
Skye Bioscience Inc. (NASDAQ:SKYE) is a clinical-stage biopharmaceutical company that focuses on developing molecules that modulate G protein-coupled receptors/GPCRs to treat obesity and metabolic diseases.
1. Newegg Commerce Inc. (NASDAQ:NEGG)
Gain Over the Past 1 Month: 164.17%
Number of Hedge Fund Holders: 2
Average Upside Potential as of July 3: 261.66%
Newegg Commerce Inc. (NASDAQ:NEGG) is one of the best hot stocks to buy according to Wall Street analysts. On June 20, Newegg Commerce announced its 11th annual FantasTech Sale, which is set to run from July 7 through July 13 this year. This major sales event will feature thousands of deals across 50+ computer and electronics product categories.
For the first time, Newegg has extended its FantasTech Price Protection program to include select items in its earlier Independence Day and Canada Day Sales. This means customers who purchased eligible products displaying the FantasTech Price Protection badge from June 30 through July 6 will automatically receive a refund for the price difference if the item’s price drops further on Newegg.com or Newegg.ca before July 13.
Refunds will be issued to the original payment method by July 22, with email confirmations sent upon processing. There is no need for customers to track prices or file claims, as Newegg’s internal systems will handle all eligible refunds. All customers on Newegg.com and Newegg.ca are automatically enrolled in the FantasTech Price Protection program for eligible purchases, with no membership required.
Newegg Commerce Inc. (NASDAQ:NEGG) is an electronics-focused e-retailer in the US, Canada, and internationally.
While we acknowledge the potential of NEGG to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than NEGG and that has 100x upside potential, check out our report about the cheapest AI stock.
READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.
Disclosure: None.
